Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Widespread adoption of the SWIFT approach, which reduces the number of clinic visits in the acute phase by ~70%, could alter how interventional psychiatry is delivered, improving patient retention and ...
Nasdaq

BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...
MedCity News

Combining Ketamine and Deep TMS: A New Frontier in Treating Depression

Unlike commonly used oral antidepressants (often known as selective serotonin reuptake inhibitors or SSRIs), ketamine works through a different mechanism. It targets glutamate pathways in the brain, ...
The Florida Times-Union

Moment of Clarity Publishes New Insight on How Deep TMS Therapy Advances Mental Health Treatment

Moment of Clarity has published a new educational resource titled “How Deep TMS Therapy Works,” providing a comprehensive overview of transcranial magnetic stimulation (TMS) and its emerging role in ...
Seeking Alpha

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression

BURLINGTON, Mass. and JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation ...
Seeking Alpha

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BWAY) (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive ...